



Product Informatiion Sheet

Polyclonal Anti- Protein kinase C gamma, PKC gamma (Magnetic Bead Conjugate)

Catalogue No. PA1234-M Immunogen

Lot No. 09F01 A synthetic peptide corresponding to a sequence at the C-terminal of human PKC

gamma, identical to the related rat and mouse sequence.

Ig type: rabbit IgG1 Purification

Immunogen affinity purified

Size: 100µg/Vial

Contents

Specificity Each vial contains 1mg/ml Magnetic Bead in PBS, pH 7.2, 0.05mg NaN₃.

Rat, mouse.

No cross reactivity with other Storage

proteins. Store at 4°C for frequent use.

Immunoprecipitation(IP) This Antagene antibody is immobilized by the covalent reaction of

hydrazinonicotinamide-modified antibody with formylbenzamide-modified magnetic beads.

It is useful for immunoprecipitation

BACKGROUND

The gamma isotype of protein kinase C (PKC gamma) is a member of the classical PKC (cPKC) subfamily which is activated by Ca(2+) and diacylglycerol in the presence of phosphatidylserine. Physiologically, PKC gamma is activated by a mechanism coupled with receptor-mediated breakdown of inositol phospholipid as other cPKC isotypes such as PKC alpha and PKC beta. PKC gamma is expressed solely in the brain and spinal cord and its localization is restricted to neurons, while PKC alpha and PKC beta are expressed in many tissues in addition to the brain. Within the brain, PKC gamma is the most abundant in the cerebellum, hippocampus and cerebral cortex, where the existence of neuronal plasticity has been demonstrated. PKC gamma gene is mutated in spinocerebellar ataxia type 14 (SCA14). Verbeek et al. (2005) point out the specific alterations in mutant PKC gamma function that could lead to the selective neuronal degeneration of SCA14.

REFERENCE

- 1. Saito N, Shirai Y (2003). "Protein kinase C gamma (PKC gamma): function of neuron specific isotype.". *J. Biochem.* 132 (5): 683–7.
- 2. Verbeek, D. S.; Knight, M. A.; Harmison, G. G.; Fischbeck, K. H.; Howell, B. W.: Protein kinase C gamma mutations in spinocerebellar ataxia 14 increase kinase activity and alter membrane targeting. *Brain* 128: 436-442, 2005.